Lung cancer is among the world’s most common cancers. In 2020 alone, there were 2.2 million new cases of lung cancer globally, and 1.8 million deaths. It is often diagnosed at a late stage, when treatment options are limited.
Early detection of lung cancer, via screening with low-dose computed tomography (LDCT), presents an opportunity to save lives and reduce the significant financial burden of lung cancer on people and societies. Only a few countries have so far committed to implementing lung cancer screening programmes, but many others are considering it.
HPP acts as Secretariat to the Lung Cancer Policy Network, an initiative of the Lung Ambition Alliance set up in 2021. The Network is a global alliance of more than 50 experts from across the lung cancer community, including clinicians, researchers, patient organisations and industry partners.
The Network’s initial goal is to create a community of exchange, through which lessons learnt from the implementation of lung cancer screening can be shared.
In 2022, we launched the Network with an inaugural report, Lung cancer screening: learning from implementation. The report showcases existing research on LDCT screening for lung cancer and draws four key lessons from successful implementation of screening programmes.
In September 2022, the Lung Cancer Policy Network will launch an interactive map collating research on the implementation of LDCT screening from around the world. The map will facilitate the sharing of best practice, showcasing examples of current organised lung cancer screening programmes and the status of early detection of lung cancer in different countries. It will be updated twice a year.
As Secretariat, HPP created and manages the Lung Cancer Policy Network’s website and Twitter account.
The Lung Cancer Policy Network is a global multidisciplinary alliance. All member donate their time for free. Please visit the Network’s website for a full list of members.
The Lung Cancer Policy Network is a global multi-stakeholder initiative set up by the Lung Ambition Alliance (founded by the International Association for the Study of Lung Cancer, Global Lung Cancer Coalition, AstraZeneca and Guardant Health). The Network is funded by AstraZeneca, Guardant Health, Johnson & Johnson and Medtronic.
